company's strategy is correctIt remains to be seen how the new rates will impact the company's profitability. The new rates kicked in in January. In the interim the company is committed to buying back up to 10% of the float and untli profitability is within acceptable bounds, the buy-back strategy makes sense. If at the same time the company makes an acquisition it will improve the top and bottom line. The price of the stock is usually influenced by the forward earning expectations and to many funds the earnings visibility is not clear hence they stay out and ignore the stock. The coming quarter the company must show that despite the reduced reimbursement rates for colonoscopies it can meet revenues and margin targets. The company said that it can do it by organic growth and acquisitions. They did not specify whether the organic growth refers to the O'Regan hemorroid procedures( up to now this has come down to us as organic growth and not through the anesthisiology part of the business.) During thr cc, i did not hear any questions to clarify the "organic growth" claim. If someone has any info on this question, let us hear it. Thannks